SG11201707989PA - Compositions containing ibrutinib - Google Patents

Compositions containing ibrutinib

Info

Publication number
SG11201707989PA
SG11201707989PA SG11201707989PA SG11201707989PA SG11201707989PA SG 11201707989P A SG11201707989P A SG 11201707989PA SG 11201707989P A SG11201707989P A SG 11201707989PA SG 11201707989P A SG11201707989P A SG 11201707989PA SG 11201707989P A SG11201707989P A SG 11201707989PA
Authority
SG
Singapore
Prior art keywords
compositions containing
containing ibrutinib
ibrutinib
compositions
Prior art date
Application number
SG11201707989PA
Inventor
Dilip Gole
Manish Kumar Gupta
Kaustubh Tambwekar
Binuraj Krishnan Nair
Maristella Bernini
Sabine Inghelbrecht
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806788&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201707989P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11201707989PA publication Critical patent/SG11201707989PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/10Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/22Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
SG11201707989PA 2015-04-06 2016-04-06 Compositions containing ibrutinib SG11201707989PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06
PCT/US2016/026134 WO2016164404A1 (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Publications (1)

Publication Number Publication Date
SG11201707989PA true SG11201707989PA (en) 2017-10-30

Family

ID=55806788

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201707989PA SG11201707989PA (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib
SG10202103458QA SG10202103458QA (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202103458QA SG10202103458QA (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Country Status (28)

Country Link
US (5) US20160287594A1 (en)
EP (3) EP3280446A1 (en)
JP (3) JP2018513852A (en)
KR (2) KR102632745B1 (en)
CN (2) CN107530293A (en)
AU (3) AU2016246669B2 (en)
CA (1) CA2981601A1 (en)
CL (1) CL2017002512A1 (en)
DK (1) DK3892302T3 (en)
EA (1) EA033992B1 (en)
ES (1) ES2964472T3 (en)
FI (1) FI3892302T3 (en)
HK (1) HK1250925A1 (en)
HR (1) HRP20231207T1 (en)
HU (1) HUE063751T2 (en)
IL (2) IL295941A (en)
LT (1) LT3892302T (en)
MA (2) MA41901A (en)
MD (1) MD3892302T2 (en)
MX (2) MX2017012822A (en)
PH (1) PH12017501811A1 (en)
PL (1) PL3892302T3 (en)
PT (1) PT3892302T (en)
RS (1) RS64653B1 (en)
SG (2) SG11201707989PA (en)
SI (1) SI3892302T1 (en)
UA (1) UA125681C2 (en)
WO (1) WO2016164404A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702548A (en) 2012-06-04 2015-11-27 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
BR112017002231A2 (en) 2014-08-07 2018-07-17 Pharmacyclics Llc new formulations of a bruton tyrosine kinase inhibitor
SG10202102078VA (en) 2015-03-03 2021-04-29 Pharmacyclics Llc Pharmaceutical formulations of a bruton’s tyrosine kinase inhibitor
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108653231A (en) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 Composition and preparation method thereof containing bruton's tyrosine kinase inhibitor
CN107014943B (en) * 2017-06-07 2018-08-21 福建省微生物研究所 A kind of detection method for replacing Buddhist nun's enantiomter according to Shandong
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
EP3687505A1 (en) 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations
US11576917B2 (en) 2018-01-20 2023-02-14 Natco Pharma Limited Pharmaceutical compositions comprising Ibrutinib
KR20190122561A (en) * 2018-04-21 2019-10-30 류형준 Lymphatic circulation promotor
CN112292117A (en) 2018-06-15 2021-01-29 詹森药业有限公司 Formulation/composition comprising ibrutinib
WO2020039264A2 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
EP3836898A2 (en) * 2018-08-18 2021-06-23 FTF Pharma Private Limited Pharmaceutical suspension for oral dosage
KR102198502B1 (en) * 2018-09-16 2021-01-05 류형준 Food composition for lymphokinesis improvement in human organism
AU2019388899A1 (en) * 2018-11-30 2021-06-10 Janssen Biotech, Inc. Methods of treating follicular lymphoma
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
KR102251435B1 (en) * 2020-11-09 2021-05-11 류형준 Food composition for treating or alleviating edema by promotion of lymphokinesis
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
WO2022260667A1 (en) * 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Oral dosage forms of ibrutinib

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166533A (en) * 2005-04-28 2008-04-23 惠氏公司 Micronized tanaproget and compostions containing same
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
EA032463B1 (en) * 2011-10-19 2019-05-31 Фармасайкликс Элэлси USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (Btk)
NZ702548A (en) * 2012-06-04 2015-11-27 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
US20150140085A1 (en) * 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
US10413687B2 (en) * 2013-03-14 2019-09-17 Fisher & Paykel Healthcare Limited Catheter mount with suction port
CA2920534A1 (en) * 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
CN105452394A (en) * 2013-08-12 2016-03-30 横滨橡胶株式会社 Primer composition
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
BR112017002231A2 (en) * 2014-08-07 2018-07-17 Pharmacyclics Llc new formulations of a bruton tyrosine kinase inhibitor
CN104523695A (en) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 Pharmaceutical composition for treating excessive proliferation diseases
CN104407067B (en) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 The detection method of Buddhist nun and isomeride thereof is replaced according to Shandong
SG10202102078VA (en) * 2015-03-03 2021-04-29 Pharmacyclics Llc Pharmaceutical formulations of a bruton’s tyrosine kinase inhibitor

Also Published As

Publication number Publication date
HK1250925A1 (en) 2019-01-18
EP4272835A2 (en) 2023-11-08
BR112017021325A2 (en) 2018-06-26
AU2016246669A1 (en) 2017-10-12
MA54411A (en) 2021-10-13
JP2022031690A (en) 2022-02-22
JP2018513852A (en) 2018-05-31
HRP20231207T1 (en) 2024-01-19
KR20240013859A (en) 2024-01-30
MD3892302T2 (en) 2024-03-31
US20230263804A1 (en) 2023-08-24
EP3892302B1 (en) 2023-09-06
LT3892302T (en) 2023-11-10
MX2017012822A (en) 2018-06-13
UA125681C2 (en) 2022-05-18
FI3892302T3 (en) 2023-11-03
CN113546054A (en) 2021-10-26
ES2964472T3 (en) 2024-04-08
US20160287594A1 (en) 2016-10-06
CA2981601A1 (en) 2016-10-13
AU2024200883A1 (en) 2024-02-29
AU2021250925B2 (en) 2023-11-16
US20170252344A1 (en) 2017-09-07
AU2016246669B2 (en) 2021-07-15
AU2021250925A1 (en) 2021-11-11
IL254695B2 (en) 2023-02-01
IL295941A (en) 2022-10-01
IL254695B (en) 2022-10-01
PH12017501811A1 (en) 2018-04-23
EP3280446A1 (en) 2018-02-14
EP3892302A1 (en) 2021-10-13
EP3892302B8 (en) 2023-10-18
US20200171036A1 (en) 2020-06-04
EP4272835A3 (en) 2023-12-20
MA41901A (en) 2021-04-14
PL3892302T3 (en) 2024-03-11
CL2017002512A1 (en) 2018-03-16
JP7438178B2 (en) 2024-02-26
CN107530293A (en) 2018-01-02
SG10202103458QA (en) 2021-05-28
US20220211713A1 (en) 2022-07-07
PT3892302T (en) 2023-11-15
IL254695A0 (en) 2017-11-30
HUE063751T2 (en) 2024-01-28
SI3892302T1 (en) 2023-11-30
MA54411B1 (en) 2023-11-30
JP2024026087A (en) 2024-02-28
EA201792224A1 (en) 2018-06-29
EA033992B1 (en) 2019-12-17
KR102632745B1 (en) 2024-02-01
MX2021015250A (en) 2022-01-24
KR20170134582A (en) 2017-12-06
RS64653B1 (en) 2023-10-31
WO2016164404A1 (en) 2016-10-13
DK3892302T3 (en) 2023-11-13

Similar Documents

Publication Publication Date Title
HK1250925A1 (en) Compositions containing ibrutinib
GB201512030D0 (en) Composition
GB201601572D0 (en) NO containing compositions
GB201505527D0 (en) Composition
GB201506827D0 (en) Composition
GB201515640D0 (en) Composition
GB201506830D0 (en) Composition
GB201506829D0 (en) Composition
GB201506825D0 (en) Composition
GB201517546D0 (en) Composition
GB201506828D0 (en) Composition
GB201518348D0 (en) Composition
GB201514585D0 (en) Composition
GB201511697D0 (en) Composition
GB201509044D0 (en) Composition
GB201505520D0 (en) Composition
GB201504665D0 (en) Composition
GB201504307D0 (en) Composition
GB2536640B (en) Epilatory compositions
GB201515639D0 (en) Composition
GB201508722D0 (en) Composition
GB201506826D0 (en) Composition
GB2536642B (en) Epilatory compositions
GB201519054D0 (en) Composition
GB201509641D0 (en) Composition